• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CYC
Click for more information
1.81% $1.36

CYCLOPHARM LIMITED - Announcements

Market Cap $166.7M  ! watchlist Created with Sketch. Add to my watchlist

Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's... Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its segments include Technegas and Molecular Imaging. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment produces radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders and cardiac disease. The Company uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. The Company distributes its products in approximately 65 countries.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
CYC Dividend/Distribution - CYC27/02/19
CYC Preliminary Final ReportPRICE SENSITIVE27/02/19
CYC CYC Update - R&D Tax Incentive, USFDA, German LitigationPRICE SENSITIVE24/01/19
CYC CANM Endorses TechnegasPRICE SENSITIVE19/12/18
CYC CYC - FNN Interview29/10/18
CYC Positive USFDA Meeting - Technegas sales expected in 2019PRICE SENSITIVE12/10/18
CYC CYC Form 484 Cancellation of Long Term Incentive Plan shares09/10/18
CYC Change of Director's Interest Notice VG17/09/18
CYC Response to ASX Appendix 3Y Query17/09/18
CYC Change of Director's Interest Notice VG12/09/18
CYC Cyclopharm FNN Investor Event04/09/18
CYC Dividend/Distribution - CYC23/08/18
CYC CYC Half Yearly Reports and AccountsPRICE SENSITIVE23/08/18
CYC Change in substantial holding from CVC13/08/18
CYC Change in substantial holding from AEF10/08/18
CYC Cyclopharm 2018 First Half Preliminary Headline UpdatePRICE SENSITIVE08/08/18
CYC Appendix 3B LTIP02/07/18
CYC Change of Director's Interest Notice28/06/18
CYC Change of Director's Interest Notice - Amended27/06/18
CYC Change of Director's Interest Notice26/06/18
CYC Change in substantial holding from CVC14/06/18
CYC Change in substantial holding from AEF13/06/18
CYC Announcement of buy-back - Appendix 3CPRICE SENSITIVE29/05/18
CYC Results of Meeting29/05/18
CYC CYC 2018 AGM PresentationPRICE SENSITIVE29/05/18
CYC Managing Director's Address to ShareholdersPRICE SENSITIVE29/05/18
CYC Chairman's Address to ShareholdersPRICE SENSITIVE29/05/18
CYC Final share buy-back notice - Appendix 3F28/05/18
CYC Better Defining Airways Disease with TechnegasPRICE SENSITIVE17/05/18
CYC Cyclopharm Acquires Scandinavian Distribution BusinessPRICE SENSITIVE07/05/18
CYC Notice of Annual General Meeting/Proxy Form27/04/18
CYC 40 Patient Milestone Achieved For Technegas USFDA TrialPRICE SENSITIVE29/03/18
CYC CYC Appendix 4G26/03/18
CYC Annual Report to shareholders26/03/18
CYC 2017 Results Presentation15/03/18
CYC Change of Director's Interest Notice - David Heaney01/03/18
CYC CYC Reports Solid FY2017 Results - Maintains Dividend26/02/18
CYC Preliminary Final ReportPRICE SENSITIVE26/02/18
CYC Dividend/Distribution - CYCPRICE SENSITIVE26/02/18
CYC FNN Interview and Presentation21/12/17
CYC Cyclopharm FNN Investor Event12/12/17
CYC Change of Director's Interest Notice - D Heaney20/11/17
CYC CYC CEO Presentation 2017 Australian Microcap ConferencePRICE SENSITIVE18/10/17
CYC Technegas USFDA Clinical Trial - Patient Enrolment UnderwayPRICE SENSITIVE26/09/17
CYC Cyclopharm acquires European distribution businessPRICE SENSITIVE20/09/17
CYC Advancing Molecular Imaging in NSWPRICE SENSITIVE19/09/17
CYC Form 484 - cancellation of Long Term Incentive Plan shares08/09/17
CYC Cyclopharm Limited 1H2017 Results Investor Presentation28/08/17
CYC Dividend/Distribution - CYC28/08/17
CYC Half Yearly Report and AccountsPRICE SENSITIVE28/08/17
CYC Nuclear imaging trial aiming to clear up airway diagnosisPRICE SENSITIVE18/08/17
CYC CYC CEO To Present at Bioshares 2017 Biotech Conference21/07/17
CYC Change in substantial holding - Chemical Trustee Limited06/07/17
CYC Change in substantial holding - Barings Acceptance Limited06/07/17
CYC Change in substantial holding from CVC04/07/17
CYC Change in substantial holding from AEF04/07/17
CYC Change of Director's Interest Notice - JMcBrayer04/07/17
CYC Change of Director's Interest Notice - VGould04/07/17
CYC Change of Director's Interest Notice - D Heaney04/07/17
CYC Appendix 3B Final30/06/17
CYC CYC Entitlement Offer Closed28/06/17
CYC CYC Notification of Shortfall28/06/17
CYC Change of Director's Interest Notice23/06/17
CYC CYC Entitlement Offer BookletPRICE SENSITIVE14/06/17
CYC Letter to Ineligible Shareholders05/06/17
CYC Letter to Eligible Shareholders05/06/17
CYC Appendix 3B05/06/17
CYC Cleansing Statement05/06/17
CYC Entitlement OfferPRICE SENSITIVE05/06/17
CYC Response to ASX query on Appendix 3Y02/06/17
CYC CYC - Positive Results of China Clinical TrialPRICE SENSITIVE01/06/17
CYC Change of Director's Interest Notice31/05/17
CYC CYC May 2017 Investor Presentation12/05/17
CYC Announcement of buy-back - Appendix 3CPRICE SENSITIVE09/05/17
CYC Results of Meeting09/05/17
CYC Managing Director's Address to ShareholdersPRICE SENSITIVE09/05/17
CYC Chairman's Address to Shareholders09/05/17
CYC CYC 2017 AGM Presentation09/05/17
CYC Final share buy-back notice - Appendix 3F08/05/17
CYC Appendix 3B19/04/17
CYC Notice of Annual General Meeting/Proxy Form07/04/17
CYC Initial Director's Interest Notice03/04/17
CYC CYC Board Changes29/03/17
CYC CYC Appendix 4G28/03/17
CYC CYC Annual Report to Shareholders28/03/17
CYC Change in substantial holding from CVC17/03/17
CYC Becoming a substantial holder - AACCF (Amended)09/03/17
CYC CYC 2016 Financial Year Results Investor Presentation06/03/17
CYC Ceasing to be a substantial holder - Lloyds (Amended)01/03/17
CYC CYC-Record Revenues and Operating EBITDA, Final Div Declared27/02/17
CYC Cyclopharm Amended 2016 Preliminary Financial ReportPRICE SENSITIVE27/02/17
CYC Dividend/Distribution - CYC22/02/17
CYC Preliminary Final ReportPRICE SENSITIVE22/02/17
CYC Becoming a substantial holder - AACCF17/02/17
CYC Ceasing to be a substantial holder - Lloyds17/02/17
CYC CYC 2016 PRELIMINARY HEADLINE UPDATE-RECORD RESULTSPRICE SENSITIVE06/02/17
CYC Release Date of 2016 Full Year Preliminary Financial Results01/02/17
CYC Change of Director's Interest Notice25/11/16
CYC CYC Achieves USFDA Agreement For Technegas Trial DesignPRICE SENSITIVE23/11/16
CYC Change of Company Address-CYC.AX 31/10/16
CYC Dividend/Distribution - CYC
27/02/19
CYC Preliminary Final Report
27/02/19PRICE SENSITIVE
CYC CYC Update - R&D Tax Incentive, USFDA, German Litigation
24/01/19PRICE SENSITIVE
CYC CANM Endorses Technegas
19/12/18PRICE SENSITIVE
CYC CYC - FNN Interview
29/10/18
CYC Positive USFDA Meeting - Technegas sales expected in 2019
12/10/18PRICE SENSITIVE
CYC CYC Form 484 Cancellation of Long Term Incentive Plan shares
09/10/18
CYC Change of Director's Interest Notice VG
17/09/18
CYC Response to ASX Appendix 3Y Query
17/09/18
CYC Change of Director's Interest Notice VG
12/09/18
CYC Cyclopharm FNN Investor Event
04/09/18
CYC Dividend/Distribution - CYC
23/08/18
CYC CYC Half Yearly Reports and Accounts
23/08/18PRICE SENSITIVE
CYC Change in substantial holding from CVC
13/08/18
CYC Change in substantial holding from AEF
10/08/18
CYC Cyclopharm 2018 First Half Preliminary Headline Update
08/08/18PRICE SENSITIVE
CYC Appendix 3B LTIP
02/07/18
CYC Change of Director's Interest Notice
28/06/18
CYC Change of Director's Interest Notice - Amended
27/06/18
CYC Change of Director's Interest Notice
26/06/18
CYC Change in substantial holding from CVC
14/06/18
CYC Change in substantial holding from AEF
13/06/18
CYC Announcement of buy-back - Appendix 3C
29/05/18PRICE SENSITIVE
CYC Results of Meeting
29/05/18
CYC CYC 2018 AGM Presentation
29/05/18PRICE SENSITIVE
CYC Managing Director's Address to Shareholders
29/05/18PRICE SENSITIVE
CYC Chairman's Address to Shareholders
29/05/18PRICE SENSITIVE
CYC Final share buy-back notice - Appendix 3F
28/05/18
CYC Better Defining Airways Disease with Technegas
17/05/18PRICE SENSITIVE
CYC Cyclopharm Acquires Scandinavian Distribution Business
07/05/18PRICE SENSITIVE
CYC Notice of Annual General Meeting/Proxy Form
27/04/18
CYC 40 Patient Milestone Achieved For Technegas USFDA Trial
29/03/18PRICE SENSITIVE
CYC CYC Appendix 4G
26/03/18
CYC Annual Report to shareholders
26/03/18
CYC 2017 Results Presentation
15/03/18
CYC Change of Director's Interest Notice - David Heaney
01/03/18
CYC CYC Reports Solid FY2017 Results - Maintains Dividend
26/02/18
CYC Preliminary Final Report
26/02/18PRICE SENSITIVE
CYC Dividend/Distribution - CYC
26/02/18PRICE SENSITIVE
CYC FNN Interview and Presentation
21/12/17
CYC Cyclopharm FNN Investor Event
12/12/17
CYC Change of Director's Interest Notice - D Heaney
20/11/17
CYC CYC CEO Presentation 2017 Australian Microcap Conference
18/10/17PRICE SENSITIVE
CYC Technegas USFDA Clinical Trial - Patient Enrolment Underway
26/09/17PRICE SENSITIVE
CYC Cyclopharm acquires European distribution business
20/09/17PRICE SENSITIVE
CYC Advancing Molecular Imaging in NSW
19/09/17PRICE SENSITIVE
CYC Form 484 - cancellation of Long Term Incentive Plan shares
08/09/17
CYC Cyclopharm Limited 1H2017 Results Investor Presentation
28/08/17
CYC Dividend/Distribution - CYC
28/08/17
CYC Half Yearly Report and Accounts
28/08/17PRICE SENSITIVE
CYC Nuclear imaging trial aiming to clear up airway diagnosis
18/08/17PRICE SENSITIVE
CYC CYC CEO To Present at Bioshares 2017 Biotech Conference
21/07/17
CYC Change in substantial holding - Chemical Trustee Limited
06/07/17
CYC Change in substantial holding - Barings Acceptance Limited
06/07/17
CYC Change in substantial holding from CVC
04/07/17
CYC Change in substantial holding from AEF
04/07/17
CYC Change of Director's Interest Notice - JMcBrayer
04/07/17
CYC Change of Director's Interest Notice - VGould
04/07/17
CYC Change of Director's Interest Notice - D Heaney
04/07/17
CYC Appendix 3B Final
30/06/17
CYC CYC Entitlement Offer Closed
28/06/17
CYC CYC Notification of Shortfall
28/06/17
CYC Change of Director's Interest Notice
23/06/17
CYC CYC Entitlement Offer Booklet
14/06/17PRICE SENSITIVE
CYC Letter to Ineligible Shareholders
05/06/17
CYC Letter to Eligible Shareholders
05/06/17
CYC Appendix 3B
05/06/17
CYC Cleansing Statement
05/06/17
CYC Entitlement Offer
05/06/17PRICE SENSITIVE
CYC Response to ASX query on Appendix 3Y
02/06/17
CYC CYC - Positive Results of China Clinical Trial
01/06/17PRICE SENSITIVE
CYC Change of Director's Interest Notice
31/05/17
CYC CYC May 2017 Investor Presentation
12/05/17
CYC Announcement of buy-back - Appendix 3C
09/05/17PRICE SENSITIVE
CYC Results of Meeting
09/05/17
CYC Managing Director's Address to Shareholders
09/05/17PRICE SENSITIVE
CYC Chairman's Address to Shareholders
09/05/17
CYC CYC 2017 AGM Presentation
09/05/17
CYC Final share buy-back notice - Appendix 3F
08/05/17
CYC Appendix 3B
19/04/17
CYC Notice of Annual General Meeting/Proxy Form
07/04/17
CYC Initial Director's Interest Notice
03/04/17
CYC CYC Board Changes
29/03/17
CYC CYC Appendix 4G
28/03/17
CYC CYC Annual Report to Shareholders
28/03/17
CYC Change in substantial holding from CVC
17/03/17
CYC Becoming a substantial holder - AACCF (Amended)
09/03/17
CYC CYC 2016 Financial Year Results Investor Presentation
06/03/17
CYC Ceasing to be a substantial holder - Lloyds (Amended)
01/03/17
CYC CYC-Record Revenues and Operating EBITDA, Final Div Declared
27/02/17
CYC Cyclopharm Amended 2016 Preliminary Financial Report
27/02/17PRICE SENSITIVE
CYC Dividend/Distribution - CYC
22/02/17
CYC Preliminary Final Report
22/02/17PRICE SENSITIVE
CYC Becoming a substantial holder - AACCF
17/02/17
CYC Ceasing to be a substantial holder - Lloyds
17/02/17
CYC CYC 2016 PRELIMINARY HEADLINE UPDATE-RECORD RESULTS
06/02/17PRICE SENSITIVE
CYC Release Date of 2016 Full Year Preliminary Financial Results
01/02/17
CYC Change of Director's Interest Notice
25/11/16
CYC CYC Achieves USFDA Agreement For Technegas Trial Design
23/11/16PRICE SENSITIVE
CYC Change of Company Address-CYC.AX
31/10/16
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$1.36 		Change
-0.025(1.81%) 		Mkt cap ! $166.7M
Open High Low Value Volume
$1.38 $1.38 $1.36 $63.10K 45.77K

Buyers (Bids)

No. Vol. Price($)
1 499 $1.36
 

Sellers (Offers)

Price($) Vol. No.
$1.40 39732 2
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
Last
$1.38 		  Change
-0.025 ( 1.61 %)
Open High Low Volume
$1.38 $1.38 $1.37 4328
Last updated 15.46pm 15/11/2024 ?
CYC (ASX) Chart

Top Stories

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Copper prices slump; Trump Wall Street rally fades; US health stocks dip on RFK appointment – and much more.
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado Blue Star Helium (ASX:BNL) has won approval from Colorado regulators to drill five fresh helium wells at its flagship.
CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.